PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-26.68%
Cash & equivalents declining -26.68% while AVXL's grows 9.21%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-26.68%
Below half of AVXL's 9.21%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-45.50%
Other current assets growth < half of AVXL's -100.00%. David Dodd sees a leaner approach to short-term items.
-27.05%
Below half of AVXL's 6.17%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.44%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both AVXL and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
12.75%
Higher Other Non-Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-5.69%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
Below half of AVXL's 6.90%. Michael Burry sees a potential red flag for stagnation or capital shortage.
9.15%
Less than half of AVXL's -31.93%. David Dodd sees a more disciplined AP approach or lower volume.
-74.86%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-9.15%
Both AVXL and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
7.01%
Less than half of AVXL's -31.93%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.56%
Higher Total Non-Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Less than half of AVXL's -31.93%. David Dodd sees far fewer liability expansions relative to competitor.
1.65%
Less than half of AVXL's 6.92%. David Dodd sees fewer share issuances vs. competitor.
-3.34%
0.5-0.75x AVXL's -5.69%. Martin Whitman is wary of weaker retention or lower profitability.
-6.51%
Less than half of AVXL's 100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-36.72%
Below half AVXL's 24.35%. Michael Burry sees potential underperformance in building shareholder capital.
-25.21%
Below half AVXL's 6.90%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both AVXL and the company show zero Total Investments Growth.
-11.75%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
27.85%
Less than half of AVXL's -9.21%. David Dodd sees better deleveraging or stronger cash buildup than competitor.